Dec 16, 2021

Shareholder Newsletter December 2021

Shareholder Newsletter December 2021

The Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Shareholder Update – December 2021 is now available to view online.

In this issue:

>> VIRALEZE™ launches in Vietnam and Italy

>> VIRALEZE™ active against Delta and other SARS-CoV-2 variants; Omicron testing planned

>> Positive DEP® cabazitaxel phase 2 interim results in advanced prostate cancer

>> DEP® docetaxel | Phase 2 clinical program

>> DEP® irinotecan | Phase 2 clinical program

>> VIRALEZE™ protects against SARS-CoV-2 in challenge model

>> VIRALEZE™ registered in Saudi Arabia, Vietnam, and New Zealand

>> Fleurstat BVgel featured in Retail Pharmacy publication

>> AZD0466 featured at ASH Meeting

>> DEP® partnerships

>> Starpharma In the Media

>> Outlook

Download: Shareholder Update December 2021 (pdf file, 849kb)

 This contains certain forward-looking statements.